Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MiNK Therapeutics, Inc. (INKT : NSDQ)

• Company Description    MiNK Therapeutics Inc. is a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. MiNK Therapeutics Inc. is headquartered in New York. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $23.25 Daily Weekly Monthly 20 Day Moving Average: 2,870,974 shares Shares Outstanding: 3.99 (millions) Market Capitalization: $92.67 (millions) Beta: 0.19 52 Week High: $52.50 52 Week Low: $4.56 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 212.92% 197.19% 12 Week 210.00% 170.00% Year To Date 233.62% 211.60%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 149 Fifth Avenue - New York,NY 10010 USA ph: 212-994-8250 fax: - investor@minktherapeutics.com http://www.minktherapeutics.com

• General Corporate Information    Officers Jennifer S. Buell - President; Chief Executive Officer and Director Garo H. Armen - Chairman Christine M. Klaskin - Treasurer Peter Behner - Director Brian Corvese - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 603693201 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 3.99 Most Recent Split Date: 1.00 (0.10:1) Beta: 0.19 Market Capitalization: $92.67 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.45 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.98 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 36.36% vs. Previous Quarter: -12.90% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -140.72 12/31/24 - -142.32 Current Ratio 06/30/25 - - 03/31/25 - 0.30 12/31/24 - 0.72 Quick Ratio 06/30/25 - - 03/31/25 - 0.30 12/31/24 - 0.72 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - -5.49 12/31/24 - -4.94 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©